Melanie Senior
As these cases go, Amgen Inc. 's patent campaign with Roche over second-generation erythropoietin holds a certain prurient interest: a Roche victory for its erythropoesis-stimulating agent CERA could...
Why EPO Matters
Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.